S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:SPNE

SeaSpine - SPNE Stock Forecast, Price & News

$7.36
+0.52 (+7.60%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.76
$7.43
50-Day Range
$5.57
$7.74
52-Week Range
$5.54
$17.34
Volume
220,676 shs
Average Volume
135,106 shs
Market Capitalization
$273.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

SeaSpine MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
307.6% Upside
$30.00 Price Target
Short Interest
Healthy
1.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
-0.11mentions of SeaSpine in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$286,500 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.43) to ($1.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

117th out of 1,117 stocks

Surgical & Medical Instruments Industry

9th out of 113 stocks

SPNE stock logo

About SeaSpine (NASDAQ:SPNE) Stock

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.

SeaSpine Price Performance

Shares of NASDAQ:SPNE traded up $0.33 during midday trading on Friday, hitting $7.17. The stock had a trading volume of 4,623 shares, compared to its average volume of 154,642. SeaSpine has a 1 year low of $5.54 and a 1 year high of $17.34. The company has a market capitalization of $266.65 million, a PE ratio of -3.79 and a beta of 1.39. The company has a quick ratio of 1.67, a current ratio of 3.49 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $6.37 and a 200-day simple moving average of $9.25.

SeaSpine (NASDAQ:SPNE - Get Rating) last announced its quarterly earnings data on Tuesday, August 2nd. The medical equipment provider reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). SeaSpine had a negative return on equity of 21.90% and a negative net margin of 32.03%. During the same period in the previous year, the company posted ($0.34) EPS. On average, sell-side analysts expect that SeaSpine will post -1.43 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the company. Piper Sandler dropped their price objective on SeaSpine from $21.00 to $12.00 and set an "overweight" rating on the stock in a report on Wednesday, August 3rd. Truist Financial dropped their price objective on SeaSpine from $20.00 to $12.00 and set a "buy" rating on the stock in a report on Wednesday, July 20th. Cantor Fitzgerald dropped their price objective on SeaSpine from $27.00 to $21.00 and set an "overweight" rating on the stock in a report on Friday, April 22nd. StockNews.com raised SeaSpine from a "sell" rating to a "hold" rating in a report on Thursday, August 4th. Finally, BTIG Research dropped their price objective on SeaSpine from $23.00 to $19.00 in a report on Thursday, June 30th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.00.

Insider Buying and Selling

In related news, insider Beau Standish sold 50,000 shares of SeaSpine stock in a transaction that occurred on Thursday, July 14th. The stock was sold at an average price of $5.73, for a total transaction of $286,500.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 9.32% of the stock is currently owned by company insiders.

Receive SPNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SeaSpine and its competitors with MarketBeat's FREE daily newsletter.

SPNE Stock News Headlines

SeaSpine (NASDAQ:SPNE) Price Target Cut to $12.00
SeaSpine Holdings's Earnings Outlook
SeaSpine (NASDAQ:SPNE) Cut to "Sell" at StockNews.com
See More Headlines
Receive SPNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SeaSpine and its competitors with MarketBeat's FREE daily newsletter.

SPNE Company Calendar

Last Earnings
8/02/2022
Today
8/12/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPNE
Fax
N/A
Employees
523
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.00
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+307.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-54,350,000.00
Pretax Margin
-33.31%

Debt

Sales & Book Value

Annual Sales
$191.45 million
Book Value
$7.71 per share

Miscellaneous

Free Float
33,722,000
Market Cap
$273.70 million
Optionable
Optionable
Beta
1.39

Key Executives

  • Mr. Keith C. Valentine (Age 54)
    Pres, CEO & Director
    Comp: $977.29k
  • Mr. John J. Bostjancic (Age 51)
    Sr. VP, CFO, COO & Treasurer
    Comp: $556.62k
  • Dr. Beau Standish P.Eng. (Age 42)
    Ph.D., Pres of Enabling Technologies
    Comp: $345.15k
  • Dr. Frank Vizesi
    Chief Scientific Officer
  • Carrie Mendivil
    Head of Investor Relations
  • Mr. Patrick L. Keran J.D. (Age 50)
    Sr. VP, Gen. Counsel & Sec.
  • Mr. John J. Winge (Age 55)
    VP of Sales
  • Ms. Hollis Winkler (Age 47)
    Sr. VP of HR
  • Mr. Tyler P. Lipschultz (Age 55)
    Sr. VP of Orthobiologics & Bus. Devel.
  • Mr. Dennis L. Cirino (Age 52)
    Sr. VP of Global Spinal Systems













SPNE Stock - Frequently Asked Questions

Should I buy or sell SeaSpine stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SPNE shares.
View SPNE analyst ratings
or view top-rated stocks.

What is SeaSpine's stock price forecast for 2022?

6 equities research analysts have issued 12 month target prices for SeaSpine's stock. Their SPNE share price forecasts range from $12.00 to $100.00. On average, they predict the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 311.5% from the stock's current price.
View analysts price targets for SPNE
or view top-rated stocks among Wall Street analysts.

How have SPNE shares performed in 2022?

SeaSpine's stock was trading at $13.62 at the beginning of 2022. Since then, SPNE stock has decreased by 46.5% and is now trading at $7.29.
View the best growth stocks for 2022 here
.

When is SeaSpine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our SPNE earnings forecast
.

How were SeaSpine's earnings last quarter?

SeaSpine Holdings Co. (NASDAQ:SPNE) issued its quarterly earnings data on Tuesday, August, 2nd. The medical equipment provider reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.03. SeaSpine had a negative trailing twelve-month return on equity of 21.90% and a negative net margin of 32.03%. During the same quarter in the prior year, the firm earned ($0.34) earnings per share.

What guidance has SeaSpine issued on next quarter's earnings?

SeaSpine updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $234.00 million-$236.00 million, compared to the consensus revenue estimate of $233.19 million.

What is Keith Valentine's approval rating as SeaSpine's CEO?

23 employees have rated SeaSpine Chief Executive Officer Keith Valentine on Glassdoor.com. Keith Valentine has an approval rating of 79% among the company's employees.

What other stocks do shareholders of SeaSpine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SeaSpine investors own include AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Kura Oncology (KURA), Recro Pharma (REPH), Rigel Pharmaceuticals (RIGL), Spectrum Pharmaceuticals (SPPI), ViewRay (VRAY), Verastem (VSTM) and Akorn (AKRX).

What is SeaSpine's stock symbol?

SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."

Who are SeaSpine's major shareholders?

SeaSpine's stock is owned by a variety of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (2.49%), Emerald Mutual Fund Advisers Trust (2.17%), Paradigm Capital Management Inc. NY (1.11%), Mutual of America Capital Management LLC (1.03%), HighMark Wealth Management LLC (0.84%) and Commonwealth Equity Services LLC (0.17%). Insiders that own company stock include Beau Standish, John B Henneman III, Keith Valentine, Renee Gaeta and Richard E Caruso.
View institutional ownership trends
.

How do I buy shares of SeaSpine?

Shares of SPNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SeaSpine's stock price today?

One share of SPNE stock can currently be purchased for approximately $7.29.

How much money does SeaSpine make?

SeaSpine (NASDAQ:SPNE) has a market capitalization of $271.12 million and generates $191.45 million in revenue each year. The medical equipment provider earns $-54,350,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.

How many employees does SeaSpine have?

The company employs 523 workers across the globe.

How can I contact SeaSpine?

SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The official website for the company is www.seaspine.com. The medical equipment provider can be reached via phone at (760) 727-8399 or via email at ir@seaspine.com.

This page (NASDAQ:SPNE) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.